Alterations of BRCA2 result in increased susceptibility to breast cancer in both men and women (relative lifetime risks of 0.06 and 0.8 respectively). BRCA2 maps to 13q12-q13 and encodes a transcript of 10 157 bp. Other cancers that have been described in BRCA2 mutation carriers include those of the larynx. Human chromosome 13q has been shown previously by LOH studies to harbor several tumor suppressor genes for head and neck squamous cell carcinoma (HNSCCs). We therefore examined the role of BRCA2 in the development of these cancers. Only 6/22 (27%) of the laryngeal cancers we examined demonstrated LOH of the BRCA2-containing region. These and 10 other HNSCCs of dierent origins that were demonstrated by LOH studies to have lost the region of chromosome 13 containing BRCA2 were examined for alterations in this gene. SSCP analysis failed to reveal any alterations leading us to conclude that BRCA2 alterations are not frequently involved in the pathogenesis of HNSCCs and that the observed LOH of chromosome 13 loci is due to other, as yet, unidenti®ed tumor suppressor gene(s). Interestingly tumors with LOH in this region (proximal to D13S118) were far more likely to be derived from women than men. This is unusual since HNSCCs are usually fourfold more common in men than in women.
Introduction
Over 42 000 new cases of head and neck squamous cell carcinomas (HNSCCs) are diagnosed per year in the United States and over 11 000 deaths occur as a result (Boring et al., 1992) . Worldwide, more than 500 000 new cases are diagnosed per year (Parkin et al., 1988) . Over 90% of these tumors occur in individuals who smoke tobacco and/or ingest alcohol (Muscat and Wynder, 1992) .
Genetic alterations in a variety of oncogenes and tumor suppressor genes have been identi®ed in HNSCCs. These include EGFR, c-myc, ras, int-2, hst-1, bcl-1, prad-1 and E-cadherin (Lee, 1992a,b) . In a small number of cases, infection with human papillomavirus (serotypes 16 and 33) has also been ascribed as a causative agent (Somers et al., 1992) . Cytogenetic analyses have revealed deletions in chromosome regions 1p, 3p, 7q, 9p, 11q and 17p (Cowan et al., 1992; Jin et al., 1993; Maestro et al., 1993; Rowley et al., 1996; Wu et al., 1994; Reed et al., 1996; Nawroz et al., 1994) . Loss of heterozygosity (LOH) studies that frequently reveal the locale of tumor suppressor genes (Ponder, 1988) have been performed by us and others and revealed regions on chromosomes 3, 8, 9, 13, 17p12 and multiple others Ah-See et al., 1994; Li et al., 1994) .
With respect to chromosome 13, several regions have been implicated to harbor alterations in HNSCCs on the basis of LOH (Lee et al., 1993 (Lee et al., , 1994 . These include regions within 13q32-qter, 13q14.2-q14.3 (Maestro et al., 1996) and 13q14.1-q22 (Yoo et al., 1994) . LOH of chromosome 13 loci precedes histological changes in 63% of the tumors, being detected in histologically normal mucosa adjacent to the tumors (Lee et al., 1994) . Known candidate tumor suppressor genes on chromosome 13 are the RB1 gene and the recently isolated gene for early-onset breast cancer 2 (BRCA2) (Wooster et al., 1995) . However, although RB1 has been localized to 13q14.2, no signi®cant variation in RB1 protein or in expression of RB1 mRNA has been detected in HNSCCs, suggesting that it is not involved in the development and/or progression of these tumors (Maestro et al., 1996; Yoo et al., 1994) and prompting a search for additional tumor suppressor genes in this vicinity.
BRCA2 is the second gene for early onset familial breast cancer to be isolated. BRCA2 maps to human chromosome 13q12-q13 (Wooster et al., 1994) . Like BRCA1, BRCA2 is a large tumor suppressor gene, with no homology to any known gene (Wooster et al., 1995) . BRCA2 alterations are estimated to account for approximately 8% of heritable early-onset breast cancer cases, 11% of heritable breast/ovarian cancer cases and 25% of male breast cancer cases with a family history of breast cancer Couch et al., 1996) . The population frequency of germline BRCA2 mutations is not known, although a mutant gene confers a lifetime risk for development of breast cancer that is similar to that for BRCA1 (approximately 70% by age 70) (Stratton, 1996) . Other cancers that have been described in BRCA2 mutation carriers include those of the larynx (Stratton et al., 1996) . Alterations in several tumor suppressor genes that are responsible for familial cancers can also cause sporadic cancers. For example, approximately 10% of ovarian tumors have been shown to harbor non-germline BRCA1 alterations (Merajver et al., 1995; Hosking et al., 1995) . In both cases, loss of the wild-type allele was observed following the classic paradigm for dominantly inherited tumor suppressor genes in which a point mutation in the coding region of one allele, inherited as a germ-line lesion, occurs in conjunction with alteration or loss of the other allele (Ponder, 1988) .
Since laryngeal cancers are over-represented in BRCA2 mutation carriers, a role for this gene in their development has been suggested (Stratton, 1996) . We therefore decided to investigate if BRCA2 is altered in sporadic HNSCCs. We ®rst examined an initial set of 72 HNSCCs for allele loss at polymorphic microsatellite loci on chromosome 13 and identi®ed 16 which exhibited LOH of the BRCA2 region. Six of these were tumors of the larynx. These 16 tumors were then screened for alterations within BRCA2 by SSCP analysis. This failed to reveal any detectable alterations indicating that BRCA2 is not frequently involved in the pathogenesis of HNSCCs.
Results and discussion
BRCA2 lies on chromosome 13q between D13S260 and D13S267. The order of loci used in this study was: 13-cen, D13S115, D13S120, D13S260, D13S267, D13S127, D13S118 and D13S126. We typed initially 70 matched tumor/normal pairs for polymorphic markers at loci that included D13S115, D13S120, D13S127, D13S126 and D13S118 (Lee et al., 1994) and demonstrated that there is increased allelic loss at multiple regions of chromosome 13. From this set of 70 tumors we identi®ed 23 that had undergone LOH of at least one locus on chromosome 13q proximal to and including D13S118, a locus that lies distal to BRCA2. This set of 23 paired samples, plus an additional two others, were examined for LOH of the region containing BRCA2 (i.e. between D13S260 and D13S267). We found that 16 of these tumors had undergone LOH at one or both of these loci and were therefore candidates for harboring BRCA2 mutations (Table 1) . These were subjected to SSCP analysis of the entire BRCA2 gene with primers/restriction endonucleases shown in Table 2 . No variants were detected in any tumor sample, suggesting that alterations in BRCA2 are not commonly found in HNSCCs.
Three sporadic breast tumors out of a total of 281 primary cancers have been reported to harbor nongerm-line BRCA2 alterations; one of these was a truncating mutation (Weber, 1996) the other two were mis-sense mutations (Miki et al., 1996; Lancaster et al., 1996) . These studies indicate that somatic BRCA2 alterations may be involved in a minor subset of sporadic breast cancers. In the study described here we were not able to detect BRCA2 mutations in 16 HNSCCs that included six laryngeal cancers, despite the fact that LOH of this region was observed in these 16 tumors. This suggests that alterations in a gene other than BRCA2 or RB1 is involved in the pathogenesis of HNSCCs. However, since SSCP will not detect all variants, it is not possible to conclusively say that there are no BRCA2 alterations within the set of 16 tumors that we examined. Also, there is speculation that some alterations in genes such as BRCA2 are not detected because they lie outside their coding regions.
One interesting observation we made during the course of this study relates to the region of chromosome 13 that was lost and the ratio of men/ women with the cancer. Overall, 19 women and 53 men were ascertained for this study. Eleven women (58% of those ascertained) and 15 men (28% of those ascertained) had LOH at or above D13S118. The remainder (eight women and 38 men) had no LOH of chromosome 13 (four women and 25 men) or had LOH at loci below D13S118 (four women and 13 (Nylander et al., 1996) .
Materials and methods

Clinical specimens
Paired HNSCC tumor tissue and blood specimens were obtained as part of a protocol approved by the University 158, 226, 219, 130, 152, 65 210, 227, 194, 170, 298 159, 159, 182, 226, 61, 115, 144, 146 209, 154, 174 103, 103, 196, 128 119, 139 9 (nc), 177, 211 199, 69 124, 164, 207, 15(nc) 144 The exon for which the corresponding primers were designed are listed in the ®rst column. Unless speci®ed the annealing temperature was 558C. The size of each exon is indicated in the second column. The third and fourth columns contain sequences of forward and reverse primers respectively. The ®fth column indicates the size of the PCR product generated with the primers provided. The sixth column indicates the enzyme/s used to generate a smaller product for SSCP and the seventh column indicates the fragment sizes generated by the corresponding enzyme. nc:non-encoding sequence.
of Texas Southwestern Medical Center Human Subjects Review Board (Table 1) . The demographic and clinical features of these patients were summarized previously (Lee et al., 1994) , with the exception of tumors no. 569/571 and 1031/1032. 569/571 was obtained from a 60 year old man with laryngeal cancer, 1031/1032 was obtained from a 39 year old woman with a tumor of the hypopharynx. All of the patients smoked tobacco and ingested alcohol. Tumors and the buy coat from blood were immediately frozen in liquid nitrogen and stored at 7708C. DNA was prepared from tumor and blood specimens by standard procedures.
Loss of heterozygosity
To identify tumors with LOH of the region containing BRCA2, tumors and matched blood specimens were genotyped for polymorphic`CA' dinucleotide repeat markers at D13S260 and D13S267 as described elsewhere (Bowcock et al., 1993) . Oligonucleotide primer sequences were obtained from the Genome Data Base. LOH studies on HNSCCs using polymorphic microsatellites are described in greater detail elsewhere (Weber et al., 1996) .
Mutational screening for BRCA2 alterations
The cDNA sequence of BRCA2 was available from Genbank (Accession No. U43746) and was aligned with genomic sequence from this region and available from the Sanger Center and Washington University (ftp://ftp/ sanger/ac/uk/pub/human/sequences/13q and ftp://genome/ wustl/edu/pub/gscl/brca2). This permitted a design of oligonucleotide primers¯anking exons/intron boundaries. Exons 10 and 11 of BRCA2 are large (1116 bp and 4932 bp respectively). They are therefore not directly amenable to SSCP analysis which is more likely to reveal variants if the fragments being tested are in the range of 130 bp. In the case of these exons, primers were designed to amplify products of approximately 1000 bp. Ampli®ed products were then digested with several dierent restriction endonucleases (Table 2) to generate fragments small enough to be examined by SSCP analysis. In the case of all other exons, primers were designed that¯anked exon/intron boundaries. PCR products from these exons were cleaved with restriction endonucleases if they were signi®cantly 4130 bp in order to generate shorter fragments lengths and these were then subjected to SSCP analysis. Primer sequences, PCR ampli®cation products, and restriction enzymes used to generate smaller products for SSCP are shown in Table 2 . DNA derived from tumor or matched blood specimens were then subjected to SSCP analysis as described by Orita et al. (1989a,b) .
SSCP analysis
PCR of tumor or matched blood DNA was performed in 20 ml volumes containing 100 ng cDNA or genomic DNA template; 16PCR buer (Perkin Elmer); 200 mM each dATP, dGTP, dCTP, dTTP; 10 pmoles each primer as shown in Table 2 (Gibco BRL); 0.3 mCi [ 32 P]dCTP (Amersham); 0.5 U Taq DNA polymerase (Perkin Elmer). PCR conditions were 30 cycles of 948C, 30 s; 558C, 30 s; 728C, 30 s. A ®nal extension reaction at 728C was performed for 7 min. Ampli®ed samples were diluted 1 : 10 in formamide buer (98% formamide, 10 mM EDTA pH 8.0, 0.05% bromophenol blue, 0.05% xylene cyanol), denatured at 958C for 5 min than cooled rapidly to 48C. For each sample, 4 ml was loaded onto an SSCP gel and run at 8 W (constant power) for 8 ± 16 h in 0.66TBE at room temperature. Gels contained 0.56MDE (AT Biochem), 0.66TBE, 160 ml 25% ammonium persulphate and 38 ml TEMED. Duplicate gels were prepared with a supplement of 10% glycerol. Gels were subjected to autoradiography with or without being dried. Film was exposed for 12 ± 24 h with an intensifying screen.
